Katja Ribbe 1 , Heidi Friedrichs 1 , Martin Begemann 1 , Sabrina Grube 1 , Sergi Papiol 1 , 30 , Anne Kästner 1 , Martin F Gerchen 1 , Verena Ackermann 1 , Asieh Tarami 1 , Annika Treitz 1 , Marlene Flögel 1 , Lothar Adler 2 , Josef B Aldenhoff 3 , Marianne Becker-Emner 4 , Thomas Becker 5 , Adelheid Czernik 6 , Matthias Dose 7 , Here Folkerts 8 , Roland Freese 9 , Rolf Günther 10 , Sabine Herpertz 11 , Dirk Hesse 12 , Gunther Kruse 13 , Heinrich Kunze 14 , Michael Franz 14 , Frank Löhrer 15 , Wolfgang Maier 16 , Andreas Mielke 17 , Rüdiger Müller-Isberner 18 , Cornelia Oestereich 19 , Frank-Gerald Pajonk 20 , Thomas Pollmächer 21 , Udo Schneider 22 , Hans-Joachim Schwarz 23 , Birgit Kröner-Herwig 24 , Ursula Havemann-Reinecke 25 , 30 , Jens Frahm 26 , 30 , 31 , Walter Stühmer 27 , 30 , 31 , Peter Falkai 25 , 30 , 31 , Nils Brose 28 , 30 , 31 , Klaus-Armin Nave 29 , 30 , 31 , Hannelore Ehrenreich , 1 , 30 , 31
10 November 2010
Schizophrenia is the collective term for an exclusively clinically diagnosed, heterogeneous group of mental disorders with still obscure biological roots. Based on the assumption that valuable information about relevant genetic and environmental disease mechanisms can be obtained by association studies on patient cohorts of ≥ 1000 patients, if performed on detailed clinical datasets and quantifiable biological readouts, we generated a new schizophrenia data base, the GRAS (Göttingen Research Association for Schizophrenia) data collection. GRAS is the necessary ground to study genetic causes of the schizophrenic phenotype in a 'phenotype-based genetic association study' (PGAS). This approach is different from and complementary to the genome-wide association studies (GWAS) on schizophrenia.
For this purpose, 1085 patients were recruited between 2005 and 2010 by an invariable team of traveling investigators in a cross-sectional field study that comprised 23 German psychiatric hospitals. Additionally, chart records and discharge letters of all patients were collected.
The corresponding dataset extracted and presented in form of an overview here, comprises biographic information, disease history, medication including side effects, and results of comprehensive cross-sectional psychopathological, neuropsychological, and neurological examinations. With >3000 data points per schizophrenic subject, this data base of living patients, who are also accessible for follow-up studies, provides a wide-ranging and standardized phenotype characterization of as yet unprecedented detail.